Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LQTS-HER: Menopausal hormone therapy and QTc in long QT syndrome
2026-526442-28-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of estradiol, estradiol + norethindrone and progesterone in menopause and Hypoestrogenemia, sponsored by Oslo University Hospital. Primary endpoint: Maximum change in QTc on ECG during each 4-week MHT period. Planned start Aug 2026; status: authorised.
02
Drugs
estradiolestradiol + norethindroneprogesterone
03
Conditions
menopauseHypoestrogenemia
Beyond the preview
Go deeper on 2026-526442-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526442-28-00.